Phenotypes associated with this allele
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Nus1tm1Wcsa mutation
(0 available);
any
Nus1 mutation
(19 available)
|
|
|
cellular
|
|
• lung endothelial cells treated with Ad-Cre show increased apoptosis
• dolichol phosphate supplementation in the media of lung endothelial cell cultures partially rescues the apoptosis defects
|
|
|
• lung endothelial cells treated with an adenovirus-expressing cre recombinase show reduced proliferation
• dolichol phosphate supplementation in the media of lung endothelial cell cultures partially rescues the proliferation defects
|
respiratory system
|
|
• total dolichol levels in lung endothelial cells treated with an adenovirus-expressing cre (Ad-Cre) recombinase are reduced
• lung endothelial cells show reduced glycosylation of VEGFR2, CD31, and VE-cad and increased ER stress markers
• dolichol phosphate supplementation in the media of lung endothelial cell cultures increases the levels of glycosylated endothelial proteins, indicating rescue of glycosylation defects
|
|
|
• lung endothelial cells treated with Ad-Cre show increased apoptosis
• dolichol phosphate supplementation in the media of lung endothelial cell cultures partially rescues the apoptosis defects
|
|
|
• lung endothelial cells treated with an adenovirus-expressing cre recombinase show reduced proliferation
• dolichol phosphate supplementation in the media of lung endothelial cell cultures partially rescues the proliferation defects
|
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Nus1tm1.1Wcsa mutation
(0 available);
any
Nus1 mutation
(19 available)
Nus1tm1Wcsa mutation
(0 available);
any
Nus1 mutation
(19 available)
|
|
|
cellular
|
|
• tamoxifen-treated mouse embryonic fibroblasts exhibit decreased cis-PTase activity in isolated membranes and mannose incorporation into proteins compared with wild-type cells
|
|
|
• in tamoxifen-treated mouse embryonic fibroblasts exposed to lovastatin
|
|
|
• tamoxifen-treated mouse embryonic fibroblasts accumulate free cholesterol compared with control mice
|
homeostasis/metabolism
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Nus1tm1Wcsa mutation
(0 available);
any
Nus1 mutation
(19 available)
Rtn4tm1Matl mutation
(1 available);
any
Rtn4 mutation
(130 available)
Tg(Cdh5-cre/ERT2)1Rha mutation
(3 available)
|
|
|
cardiovascular system
|
N |
• embryos from tamoxifen-treated pregnant females at E8.5 do not show vascular defects
|
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Nus1tm1Wcsa mutation
(0 available);
any
Nus1 mutation
(19 available)
Tg(Tek-cre)12Flv mutation
(1 available)
|
|
|
mortality/aging
|
|
• lethality between E10.5 and E11.5
|
growth/size/body
|
|
• embryos are smaller at E10.5 but not at E8.5 or E9.5
|
embryo
|
|
• placentas show dilated embryonic vessels and decreased numbers of embryonic vessels
|
|
|
• yolk sacs are poorly organized with dilated primitive capillaries and have no large vitelline vessels
|
|
|
• E10.5 embryos are paler than controls
|
|
|
• embryos are smaller at E10.5 but not at E8.5 or E9.5
|
|
|
• the labyrinthine layers of the placenta are thinner
|
|
|
• yolk sacs are dimpled and wrinkled at E9.5
|
|
|
• yolk sacs at E9.5 show 39% reductions in endothelial cell proliferation
• yolk sacs at E9.5 show increased apoptosis of endothelial cells
|
cardiovascular system
|
|
• placentas show dilated embryonic vessels and decreased numbers of embryonic vessels
|
|
|
• yolk sacs are poorly organized with dilated primitive capillaries and have no large vitelline vessels
|
|
|
• hypoglycosylation of endothelial proteins including VEGFR2
|
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Nus1tm1Wcsa mutation
(0 available);
any
Nus1 mutation
(19 available)
Tg(Cdh5-cre/ERT2)1Rha mutation
(3 available)
|
|
|
mortality/aging
|
|
• embryos from tamoxifen-treated females at E8.5 and E9.5 die 5 days after tamoxifen injection
|
embryo
|
|
• yolk sacs show vascular defects in embryos from tamoxifen-treated females at E8.5 and E9.5
|
|
|
• embryos from tamoxifen-treated females at E8.5 and E9.5 show blood filled jugular lymph sacs at E13.5
|
cardiovascular system
|
|
• embryos from tamoxifen-treated females at E8.5 and E9.5 show dilation of subcutaneous microvessels and blood filled jugular lymph sacs at E13.
• reduction in vascular density and disorganized vascular networks are seen in embryonic tissues (hindbrain, skin, and hindlimb) of embryos from tamoxifen-treated females at E8.5 and E9.5
|
|
|
• yolk sacs show vascular defects in embryos from tamoxifen-treated females at E8.5 and E9.5
|
|
|
• embryos from tamoxifen-treated females at E8.5 and E9.5 exhibit extensive multifocal subcutaneous hemorrhages at E12.5 and E13.5
|
|
|
• dorsal skin of embryos from tamoxifen-treated females show increased apoptosis
|
cellular
|
|
• dorsal skin of embryos from tamoxifen-treated females show increased apoptosis
|
|
|
• embryos from tamoxifen-treated females at E8.5 and E9.5 show 48% reductions in endothelial cell proliferation at E12.5
|
homeostasis/metabolism
immune system
|
|
• embryos from tamoxifen-treated females at E8.5 and E9.5 show blood filled jugular lymph sacs at E13.5
|
integument
|
|
• embryos from tamoxifen-treated females at E8.5 and E9.5 exhibit subcutaneous edema
|
Analysis Tools